Slovenien - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

chanelle pharmaceuticals manufacturing ltd -

Den Europæiske Union - slovensk - EMA (European Medicines Agency)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hipofize in hipotalamični hormoni in analogi - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

Den Europæiske Union - slovensk - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotična sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Den Europæiske Union - slovensk - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hipertenzija - sredstva, ki delujejo na sistem renin-angiotenzin - zdravljenje esencialne hipertenzije.

Slovenien - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amomed pharma gmbh - imatinib - filmsko obložena tableta - imatinib 100 mg / 1 tableta - imatinib

Slovenien - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amomed pharma gmbh - imatinib - filmsko obložena tableta - imatinib 400 mg / 1 tableta - imatinib

Den Europæiske Union - slovensk - EMA (European Medicines Agency)

allergan pharmaceuticals international ltd - prašek trebušne slinavke - eksocrine pankreasne pomanjkljivosti - digestivi, vklj. encimi - zdravljenje s pankreatičnimi encimi pri eksokrinalni insuficienci pankreasa zaradi cistične fibroze ali drugih stanj (e. kronični pankreatitis, post pancreatectomy ali rak trebušne slinavke). enzepi je navedeno v dojenčki, otroci, mladostniki in odrasli.

Den Europæiske Union - slovensk - EMA (European Medicines Agency)

teva b.v. - ribavirin - hepatitis c, kronični - antivirusi za sistemsko uporabo - ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) in adults (see sections 4. 2, 4. 4 in 5. ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4. 2, 4. 4 in 5.

Den Europæiske Union - slovensk - EMA (European Medicines Agency)

mylan s.a.s. - pregabalin - anxiety disorders; neuralgia; epilepsy - antiepileptics, - epilepsypregabalin mylan pharma je označen kot adjunctive terapija pri odraslih z delni epileptični napadi z ali brez sekundarne posplošitev. splošne anksioznosti disorderpregabalin mylan pharma je primerna za zdravljenje splošne anksiozne motnje (gad) pri odraslih.

Slovenien - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

octapharma (ip) ltd., - koagulacijski faktor ii, humani; koagulacijski faktor ix, humani; koagulacijski faktor viii, humani; koagulacijski faktor x, humani; protein c; protein s; koagulacijski faktor ix, humani - prašek in vehikel za raztopino za infundiranje - koagulacijski faktor ii, humani 1520 i.e. / 1 viala  koagulacijski faktor ix, humani1000 i.e. / 1 viala  koagulacijski faktor viii, humani960 i.e. / 1 viala  koagulacijski faktor x, humani1200 i.e. / 1 viala  protein c1240 i.e. / 1 viala  protein s1280 i.e. / 1 viala  koagulacijski faktor ix, humani1000 i.e. / 1 viala; koagulacijski faktor ix, humani 1000 i.e. / 1 viala  koagulacijski faktor viii, humani960 i.e. / 1 viala  koagulacijski faktor x, humani1200 i.e. / 1 viala  protein c1240 i.e. / 1 viala  protein s1280 i.e. / 1 viala  koagulacijski faktor ix, humani1000 i.e. / 1 viala; koagulacijski faktor viii, humani 960 i.e. / 1 viala  koagulacijski faktor x, humani1200 i.e. / 1 viala  protein c1240 i.e. / 1 viala  protein s1280 i.e. / 1 viala  koagulacijski faktor ix, humani1000 i.e. / 1 viala; koagulacijski faktor x, humani 1200 i.e. / 1 viala  protein c1240 i.e. / 1 viala  protein s1280 i.e. / 1 viala  koagulacijski faktor ix, humani1000 i.e. / 1 viala; protein c 1240 i.e. / 1 viala  protein s1280 i.e. / 1 viala  koagulacijski faktor ix, humani1000 i.e. / 1 viala; protein s 1280 i.e. / 1 viala  koagulacijski faktor ix, humani1000 i.e. / 1 viala; koagulacijski faktor ix, humani 1000 i.e. / 1 viala - kombinacije koagulacijskih faktorjev ix, ii, vii in x